Walleye Capital
ABBV icon

Walleye Capital’s AbbVie ABBV Stock Holding History

Walleye Capital’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$16.2M Sell
74,700
-106,300
-59% -$23.6M 0.07% 250
2025
Q4 		$41.4M Buy
181,000
+136,400
+306% +$31.1M 0.13% 93
2025
Q3 		$10.3M Sell
44,600
-65,000
-59% -$13.2M 0.04% 532
2025
Q2 		$20.3M Buy
109,600
+7,900
+8% +$1.47M 0.08% 226
2025
Q1 		$21.3M Sell
101,700
-19,800
-16% -$3.85M 0.1% 181
2024
Q4 		$21.6M Sell
121,500
-12,300
-9% -$2.26M 0.05% 304
2024
Q3 		$26.4M Buy
133,800
+39,500
+42% +$7.37M 0.06% 250
2024
Q2 		$16.2M Sell
94,300
-123,700
-57% -$20.5M 0.03% 467
2024
Q1 		$39.7M Buy
218,000
+109,200
+100% +$18.8M 0.07% 188
2023
Q4 		$16.9M Sell
108,800
-41,500
-28% -$6.05M 0.04% 412
2023
Q3 		$22.4M Buy
150,300
+91,100
+154% +$13.4M 0.06% 220
2023
Q2 		$7.98M Buy
59,200
+8,500
+17% +$1.25M 0.03% 493
2023
Q1 		$8.08M Buy
50,700
+7,600
+18% +$1.16M 0.12% 187
2022
Q4 		$6.97M Buy
43,100
+13,900
+48% +$2.13M 0.13% 196
2022
Q3 		$3.92M Buy
+29,200
New +$4.19M 0.07% 285
2020
Q2 		– Sell
-9,100
Closed -$693K – 589
2020
Q1 		$693K Sell
9,100
-291,000
-97% -$24.8M 0.15% 181
2019
Q4 		$26.6M Buy
300,100
+54,400
+22% +$4.52M 1.72% 1
2019
Q3 		$18.6M Buy
245,700
+169,400
+222% +$11.6M 1.11% 1
2019
Q2 		$5.55M Buy
76,300
+30,100
+65% +$2.37M 0.61% 8
2019
Q1 		$3.72M Buy
+46,200
New +$3.78M 0.61% 1

Other funds holding ABBV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Walleye Capital's ABBV Position: Q1 2026 in Review

Walleye Capital reduced its AbbVie (ABBV) stake by 36% in Q1 2026, selling an estimated $13.5M and leaving 110,005 shares worth $23.9M. The position accounts for 0.1% of the portfolio, ranked #145.

Walleye Capital first reported a position in ABBV in Q1 2019 and has held it in 20 quarters since. The position peaked at $43.1M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Walleye Capital held 110,005 shares of AbbVie worth $23.9M as of Q1 2026.
  • Walleye Capital sold 60,736 AbbVie shares in Q1 2026, an estimated $13.5M.
  • AbbVie made up 0.1% of Walleye Capital's portfolio in Q1 2026, its #145 holding.
  • Walleye Capital first reported a position in AbbVie in Q1 2019 and has held it in 20 quarters since.
  • Walleye Capital's AbbVie position peaked at $43.1M in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.